Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inozyme Pharma, Inc.
Report date July 01, 2025 · Filed July 03, 2025
Section 16 reporting ended · disclosed 2025-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Other · Disposed 43,861 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.77 · Expires 2030-05-27 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-01 · Disposition to issuer · Disposed 86,979 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2035-03-10 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-01 · Disposition to issuer · Disposed 400,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F3: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
Ra Pharmaceuticals, Inc.
Report date April 02, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 1
1 source rowRow 1 · 2020-04-02 · Disposition to issuer · Disposed 234,707 · Balance 0 F1: Includes (i) 377 shares of Issuer common stock acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2019 and (ii) 14,620 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2025-12-10 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-02 · Disposition to issuer · Disposed 139,371 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2025-12-10 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-02 · Disposition to issuer · Disposed 241,460 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2026-08-16 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-02 · Disposition to issuer · Disposed 164,285 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2027-02-01 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-02 · Disposition to issuer · Disposed 225,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.33 · Expires 2028-02-01 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-02 · Disposition to issuer · Disposed 125,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-04-02 · Disposition to issuer · Disposed 311,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-04-02 · Disposition to issuer · Disposed 20,833 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (i) 377 shares of Issuer common stock acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2019 and (ii) 14,620 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020.
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
F4: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $51.84 | $0.00 |
DisclosureSEC source: 0001193125-26-264279 · ownership.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:06 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 20,000 | $57.03 | $1,140,600.00 |
DisclosureSEC source: 0001688192-25-000004 · ownership.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 F1 · kind: Open market purchase of shares in accordance with Issuer's trading policies. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.92 to $57.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:03 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0000950170-25-094091 · ownership.xml · derivative · entry 4 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2035-03-10 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:03 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Disposition to issuerStock Option (Right to Buy) · Derivative | 86,979 | Not disclosed Strike: $2.77 | Not disclosed |
DisclosureSEC source: 0000950170-25-094091 · ownership.xml · derivative · entry 3 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 86,979 shares Expires 2030-05-27 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:03 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Disposition to issuerRestricted Stock Units · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-094091 · ownership.xml · derivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:03 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | OtherCommon Stock | 43,861 | $4.00 | $175,444.00 |
DisclosureSEC source: 0000950170-25-094091 · ownership.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 16:05 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantCommon Stock | 2,815 | $0.74 | $2,083.10 |
DisclosureSEC source: 0000950170-25-090864 · ownership.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,861 F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $38.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083273 · ownership.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document |
| April 02, 2025 Filed Apr 3, 2025 16:27 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | SaleCommon Stock | 8,819 | $0.89 | $7,848.91 |
DisclosureSEC source: 0000950170-25-050443 · ownership.xml · nonDerivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,046 F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 16:27 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050443 · ownership.xml · derivative · entry 3 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F4 · derivative.exercise_date: On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. F4 · derivative.expiration_date: On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 16:27 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050443 · ownership.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO & Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F2 · balance_after: Includes 2,490 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 31, 2025. Read SEC document |
| March 11, 2025 Filed Mar 17, 2025 16:24 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-040314 · ownership.xml · derivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028. F3 · derivative.exercise_date: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028. F3 · derivative.expiration_date: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028. Read SEC document |
| March 11, 2025 Filed Mar 17, 2025 16:24 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-25-040314 · ownership.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-03-10 F1 · derivative.exercise_price: The exercise price represents the closing price of the Issuer's common stock on March 11, 2025. F2 · derivative.exercise_date: The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| September 30, 2024 Filed Oct 3, 2024 20:58 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantCommon Stock | 1,710 | $4.45 | $7,609.50 |
DisclosureSEC source: 0000950170-24-112695 · ownership.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,375 F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2024 through September 30, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2024, the last trading day of the purchase period. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $54.06 | $0.00 |
DisclosureSEC source: 0000950170-24-067323 · ownership.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2034-05-30 F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 17:23 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | SaleCommon Stock | 7,523 | $6.94 | $52,209.62 |
DisclosureSEC source: 0000950170-24-041301 · ownership.xml · nonDerivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,665 F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 17:23 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-041301 · ownership.xml · derivative · entry 3 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F5 · derivative.exercise_date: On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. F5 · derivative.expiration_date: On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 17:23 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-041301 · ownership.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F2 · balance_after: Includes 3,188 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 28, 2024. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 08:30 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0000950170-24-031877 · ownership.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-03-12 F1 · derivative.exercise_date: The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 21:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $62.59 | $0.00 |
DisclosureSEC source: 0001209191-23-035980 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:05 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantRestricted stock units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022649 · doc4.xml · derivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. F3 · derivative.exercise_date: The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:05 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock option (right to buy) · Derivative | 800,000 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001209191-23-022649 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common stock · 800,000 shares Expires 2033-03-31 F1 · derivative.exercise_price: The exercise price represents the closing price of the Issuer's common stock on March 31, 2023. F2 · derivative.exercise_date: The option was granted on April 1, 2023 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 07:52 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-22-036570 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $71.70 | $0.00 |
DisclosureSEC source: 0001209191-22-036053 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 16:16 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $17.12 | $0.00 |
DisclosureSEC source: 0001209191-21-043009 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2031-06-22 F1 · derivative.exercise_date: The option was granted on June 23, 2021. The shares underlying the option are scheduled to vest as to 100% of the shares on June 23, 2022, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040297 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:50 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 9,367 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020402 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,367 Underlying: Common Stock · 9,367 shares Expires 2030-07-22 F1 · derivative.exercise_date: The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0001209191-20-036641 · doc4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2020 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerRestricted Stock Units · Derivative | 20,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 8 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,833 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 311,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 7 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 311,000 shares Expires 2029-02-01 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 6 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2028-02-01 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 5 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2027-02-01 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 164,285 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 4 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,285 shares Expires 2026-08-16 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 241,460 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 3 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241,460 shares Expires 2025-12-10 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 139,371 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · derivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 139,371 shares Expires 2025-12-10 F2 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 13:02 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerCommon Stock | 234,707 | $48.00 | $11,265,936.00 |
DisclosureSEC source: 0001104659-20-042773 · a4.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes (i) 377 shares of Issuer common stock acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2019 and (ii) 14,620 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:38 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionRestricted Stock Units · Derivative | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-005904 · a4.xml · derivative · entry 4 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,666 Underlying: Common Stock · 20,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: On February 1, 2018, the reporting person was granted 62,500 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:38 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 311,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001104659-19-005904 · a4.xml · derivative · entry 3 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,000 Underlying: Common Stock · 311,000 shares Expires 2029-02-01 F2 · derivative.exercise_date: These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:38 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Tax withholdingCOMMON STOCK | 6,327 | $21.00 | $132,867.00 |
DisclosureSEC source: 0001104659-19-005904 · a4.xml · nonDerivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,799 Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:38 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Exercise / conversionCOMMON STOCK | 20,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-005904 · a4.xml · nonDerivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:45 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-006633 · a4.xml · derivative · entry 2 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires not disclosed F2 · derivative.exercise_date: These RSUs vest in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 02:45 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 125,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-18-006633 · a4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: These stock options vest in 48 equal monthly installments on each monthly anniversary thereafter following February 1, 2018, the grant date. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:28 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 225,000 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001104659-17-006443 · a4.xml · derivative · entry 1 Treco Douglas A · CIK 0001688192 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.